Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of CsA Ophthalmic Gel in Moderate to Severe Dry Eye Disease
NCT04541888Phase 3Completed
- Sponsor
- Zhaoke Ophthalmology
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cyclosporine 2% ophthalmic solution in dry eye disease (DED) (2 arms), sponsored by Zhaoke Ophthalmology. Primary endpoint: Inferior Corneal Staining Score at Day 84. Started Nov 2020; status: completed.
02
Drugs
cyclosporine 2% ophthalmic solution
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04541888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541888.